New Zealand markets closed

ABBV Jan 2024 80.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
2.0200-0.2300 (-10.22%)
At close: 12:57PM EDT
Full screen
Previous close2.2500
Open2.0000
Bid1.6500
Ask2.2800
Strike80.00
Expiry date2024-01-19
Day's range2.0000 - 2.0200
Contract rangeN/A
Volume3
Open interest743
  • Zacks

    Pharma Stock Roundup: FDA OK's Expanded Use of ABBV, MRK, NVS Drugs, Other Updates

    The FDA approves expanded use of AbbVie's (ABBV) Skyrizi, Merck's (MRK) Vaxneuvance vaccine and Novartis's (NVS) cancer combination drugs, Tafinlar (dabrafenib) + Mekinist (trametinib).

  • Motley Fool

    Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip

    As prices go down, yields go up, and that dynamic has made both Target (NYSE: TGT) and AbbVie (NYSE: ABBV) excellent choices for bargain-hunters searching for quality companies with yields well above the current 1.7% average of S&P 500 index stocks. For quite some time, Target was the retail stock that could do no wrong. The company repeatedly posted revenue growth and strong profitability, even through the pandemic, and there was little indication of serious trouble.

  • Zacks

    AbbVie (ABBV) Files Qulipta sNDA for Chronic Migraine Prevention

    With the latest approval for chronic migraine prevention, AbbVie's(ABBV) Qulipta becomes the only CGRP receptor antagonist approved for a broad preventive treatment of migraine indication.